Table C.16Model 2 base case resuts: cost per QALY gained

StrategyCostEffectivenessIncrement C/E (ICER)
All strategies
No testing strategy£1.90.00050 QALY
Reagent 1 strategy£16.90.00053 QALY489,899/QALY
ACR strategy£18.30.00054 QALY411,726/QALY
Reagent 2 strategy£21.80.00054 QALY(Dominated)
Without dominated options (simple or extended)
No testing strategy£1.90.00050 QALY
ACR strategy£18.30.00054 QALY482,082 /QALY

From: Appendix C, Health economic model – Cost effectiveness of CKD case finding among people at high risk

Cover of Chronic Kidney Disease
Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care.
NICE Clinical Guidelines, No. 73.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.